23 completed, 5 terminated, 2 unknown. 30 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 30 | Completed 23, Terminated 5, Unknown 2 |
Follow paricalcitol: new trials by email Literature Review of paricalcitol trials Research Report on paricalcitol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol - Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency | Phase 4 | Completed | OPKO Health, Inc. | 69 | 2018-06-08 | 2022-12-09 |
| Paricalcitol Improves Anemia of Inflammation Paricalcitol, Epoetin beta, Placebo - Anemia | Phase 4 | Terminated | Hospital Son Espases | 19 | 2014-12-01 | 2024-12-09 |
| Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Paricalcitol, Calcifediol - Secondary Hyperparathyroidism Due to Renal Causes | Phase 4 | Completed | Fundación Senefro | 148 | 2014-01-01 | 2018-11-19 |
| Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Calcitriol, Paricalcitol - Kidney Failure, Secondary Hyperparathyroidism | Phase 4 | Terminated | Winthrop University Hospital | 16 | 2012-11-01 | 2023-11-07 |
| Effect of Paricalcitol Over Vessel Wall Paricalcitol - Nephropathy | Phase 4 | Terminated | Effice Servicios Para la Investigacion S.L. | 50 | 2012-07-01 | 2015-02-26 |
| A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Paricalcitol, Darbepoetin alfa - Moderate to Severe Secondary Hyperparathyroidism, Stage 5 Chronic Kidney Diseases | Phase 4 | Completed | AbbVie (prior sponsor, Abbott) | 65 | 2012-05-10 | 2021-07-30 |
| Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D Hidroferol®, Paricalcitol: Zemplar®, Habitual medication - Kidney Failure, Chronic, Disorder of Vitamin D | Phase 4 | Unknown | Hospital Universitario de Canarias | 174 | 2012-01-01 | 2012-05-21 |
| Intravenous Paricalcitol in Chronic Hemodialysis Patients Intravenous Paricalcitol - Endstage Renal Disease, Secondary Hyperparathyroidism | Phase 4 | Unknown | The University of Hong Kong | 30 | 2011-09-01 | 2017-01-18 |
| Paricalcitol Effect on Anemia in CKD Paricalcitol, Calcitriol - Anemia, Chronic Kidney Disease | Phase 4 | Completed | Federico II University | 60 | 2010-10-01 | 2014-07-30 |
| The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate Paricalcitol - Chronic Kidney Disease | Phase 4 | Completed | Indiana University | 16 | 2010-08-01 | 2013-05-21 |
| Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy Paricalcitol - Cardiovascular Disease, Diabetic Nephropathy | Phase 4 | Completed | Peter Rossing | 48 | 2010-04-01 | 2012-04-13 |
| Trial to Optimize Mineral Outcomes in Dialysis Patients Cinacalcet, active vitamin D analogue - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 4 | Completed | University of Colorado, Denver | 92 | 2010-03-01 | 2017-01-02 |
| Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Paricalcitol, Cinacalcet - Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 4 | Completed | Abbott | 272 | 2009-11-01 | 2012-06-20 |
| Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients Paricalcitol, Calcitriol, Cholecalciferol - Cardiorenal Syndrome, Chronic Allograft Nephropathy | Phase 4 | Completed | Ural State Medical University | 109 | 2009-10-01 | 2015-06-09 |
| Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Paricalcitol, Ergocalciferol - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 4 | Completed | Salem Veterans Affairs Medical Center | 80 | 2009-07-01 | 2011-03-24 |
| Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Zemplar (paricalcitol) - Secondary Hyperparathyroidism, Renal Insufficiency, Chronic | Phase 4 | Completed | Abbott | 100 | 2009-05-01 | 2011-10-31 |
| Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Paricalcitol, Calcitriol - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 4 | Completed | Washington University School of Medicine | 110 | 2009-02-01 | 2014-08-07 |
| Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects Calcitriol, Paricalcitol - Secondary Hyperparathyroidism, Dialysis | Phase 4 | Terminated | Abbott | 13 | 2009-01-01 | 2012-01-20 |
| Vitamin D and Coronary Calcification Study Calcitriol (Rocaltrol®), Paricalcitol - Chronic Kidney Disease, Vitamin D Deficiency | Phase 4 | Completed | Joslin Diabetes Center | 44 | 2008-09-01 | 2017-12-08 |
| Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Paricalcitol injection, Paricalcitol capsules - Secondary Hyperparathyroidism, Dialysis | Phase 4 | Completed | Abbott | 147 | 2007-09-01 | 2011-10-25 |
Showing 20 of 30. Sign in to see all of them.
Hyperparathyroidism, Secondary (18) · Renal Insufficiency, Chronic (12) · Kidney Failure, Chronic (6) · Hypercalcemia (4) · Hyperparathyroidism (3) · Anemia (2) · Hyperphosphatemia (2) · Kidney Diseases (2) · Renal Insufficiency (2) · Vitamin D Deficiency (2) · Cardio-Renal Syndrome (1) · Cardiovascular Diseases (1) · Diabetic Nephropathies (1) · Inflammation (1)
Abbott (9) · Genzyme, a Sanofi Company (2) · AbbVie (prior sponsor, Abbott) (1) · Amgen (1) · Effice Servicios Para la Investigacion S.L. (1) · Federico II University (1) · Fresenius Medical Care North America (1) · Fundación Senefro (1) · Hospital Son Espases (1) · Hospital Universitario de Canarias (1) · Indiana University (1) · Joslin Diabetes Center (1) · OPKO Health, Inc. (1) · Papageorgiou General Hospital (1) · Peter Rossing (1)
United States (15) · Spain (4) · Denmark (2) · Greece (2) · Italy (2) · Netherlands (2) · Russia (2) · Brazil (1) · Czechia (1) · Germany (1) · Hong Kong (1) · Mexico (1) · Peru (1) · Portugal (1) · Sweden (1)
Alexander Kharlamov, M.D. (1) · Alexander Perrish, M.D. (1) · Angela YM Wang, MD PhD (1) · Csaba P. Kovesdy, M.D. (1) · Daniel W Coyne, MD (1) · David M Spiegel, MD (1) · Efstathios Mitsopoulos, MD (1) · Eleonora Riccio, MD (1) · Jin Tian, M.D. (1) · Josep M Cruzado, Dr (1) · Laura Williams, M.D. (1) · Lino Rodrigues, MD (1)
PMID 21716260, PMID 22387567, PMID 22839442, PMID 24214232, PMID 24500308, PMID 24970869, PMID 25781618, PMID 32775985
2009 (2)